BioSante Female Libido Drug Hype Was Fraudulent: Suit

Law360, New York (February 6, 2012, 12:09 PM EST) -- An investor hit BioSante Pharmaceuticals Inc. with a securities fraud class action Friday in Illinois claiming CEO Stephen Simes told tall tales about how an experimental women's libido drug was bound for torrid sales before clinical results threw cold water on shareholders.

By the time the Lincolnshire, Ill.-based company told investors in December that late-stage tests had shown its LibiGel drug was no better than a placebo at making women feel frisky, Simes had spent more than a year hyping the drug's prospects — and BioSante...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Lauria v. BioSante Pharmaceuticals, Inc. et al


Case Number

1:12-cv-00772

Court

Illinois Northern

Nature of Suit

850(Securities/Commodities)

Judge

Honorable Joan B. Gottschall

Date Filed

February 2, 2012

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.